Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer

Advanced Drug Delivery Reviews

Volumn 61, Issue 7-8, 2009, Pages 572-588

  Lu, Yi ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Adenovirus; GDEPT; Oncolytic virotherapy; Prostate specific promoter; Replication competent; Transgene; Viral vectors

Indexed keywords

ADENOVIRUS; GDEPT; ONCOLYTIC VIROTHERAPY; PROSTATE-SPECIFIC PROMOTER; REPLICATION-COMPETENT; TRANSGENE; VIRAL VECTORS;

STRATEGIC PLANNING;

GENETIC ENGINEERING;

ADENOVIRUS VECTOR; ADMMTVLACZ VECTOR; ADPBLACZ VECTOR; ADPSAE1 VECTOR; ADPSALACZ VECTOR; ADRSVLACZ VECTOR; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG; VIRUS VECTOR;

CANCER GENE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; GENE TARGETING; IMMUNOMODULATION; NONVIRAL GENE DELIVERY SYSTEM; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SUICIDE GENE THERAPY; TRANSCRIPTION REGULATION; TRANSGENE;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TARGETING; GENETIC VECTORS; HUMANS; MALE; ONCOLYTIC VIROTHERAPY; PROSTATIC NEOPLASMS; TRANSCRIPTION, GENETIC; TRANSGENES; VIRUSES;

EID: 65749102436     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.03.014     Document Type: Review

References (228)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
2. Partin A.W., and Oesterling J.E. The clinical usefulness of prostate specific antigen: update 1994. J. Urol. 152 (1994) 1358-1368
3. Nishikawa M., and Hashida M. Nonviral approaches satisfying various requirements for effective in vivo gene therapy. Biol. Pharm. Bull. 25 (2002) 275-283
4. Pawelek J.M., Low K.B., and Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 57 (1997) 4537-4544
5. Buchschacher G.L., and Wong-Staal F. Development of lentiviral vectors for gene therapy for human diseases. Blood 95 (2000) 2499-2504
6. Berkner K.L. Development of adenovirus vectors for the expression of heterologous genes. BioTechniques 6 (1988) 616-629
7. Miller A.D., and Rosman G.J. Improved retroviral vectors for gene transfer and expression. BioTechniques 7 (1989) 980-990
8. Moss B. Vaccinia virus: a tool for research and vaccine development. Science 252 (1991) 1662-1666
9. Flotte T.R., and Carter B.J. Adeno-associated viruses as vectors for gene therapy. Gene Ther. 2 (1995) 357-362
10. Krisky D., Marconi P., Goins W.F., and Glorioso J.C. Development of replication-defective herpes simplex virus vectors. In: Robbins P.D. (Ed). Gene Therapy Protocols (1997), Humana Press 79-102
11. Yonemitsu Y., Ueda Y., Kinoh H., and Hasegawa M. Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen. Front. Biosci. 13 (2008) 4953-4959
12. Romano G. Current development of lentiviral-mediated gene transfer. Drug News Perspect. 18 (2005) 128-134
13. Berges R.R., Furuya Y., Remington L., and English H.F. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc. Natl. Acad. Sci. USA 90 (1993) 8910-8914
14. Lu Y., Carraher J., Zhang Y., Armstrong J., Lerner J., Roger W., and Steiner M.S. Delivery of adenoviral vectors to the prostate for gene therapy. Cancer Gene Ther. 6 (1999) 64-72
15. Teh B.S., Aguilar-Cordova E., Kernen K., Chou C.C., Shalev M., Vlachaki M.T., Miles B., Kadmon D., Mai W.Y., Caillouet J., Davis M., Ayala G., Wheeler T., Brady J., Carpenter L.S., Lu H.H., Chiu J.K., Woo S.Y., Thompson T., and Butler E.B. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer-a preliminary report. Int. J. Radiat. Oncol. Biol. Phys. 51 (2001) 605-613
16. DeWeese T.L., van der Poel H., Li S., Mikhak B., Drew R., Goemann M., Hamper U., DeJong R., Detorie N., Rodriguez R., Haulk T., DeMarzo A.M., Piantadosi S., Yu D.C., Chen Y., Henderson D.R., Carducci M.A., Nelson W.G., and Simons J.W. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61 (2001) 7464-7472
17. Herman J.R., Adler H.L., Aguilar-Cordova E., Rojas-Martinez A., Woo S., Timme T.L., Wheeler T.M., Thompson T.C., and Scardino P.T. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum. Gene Ther. 10 (1999) 1239-1249
18. Miles B.J., Shalev M., Aguilar-Cordova E., Timme T.L., Lee H.M., Yang G., Adler H.L., Kernen K., Pramudji C.K., Satoh T., Gdor Y., Ren C., Ayala G., Wheeler T.M., Butler E.B., Kadmon D., and Thompson T.C. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum. Gene Ther. 12 (2001) 1955-1967
19. Toietta G., Mane V.P., Norona W.S., Finegold M.J., Ng P., McDonagh A.F., Beaudet A.L., and Lee B. Lifelong elimination of hyperbilirubenemia in the Gunn rat with a single injection of helper-dependent adenoviral vector. Proc. Natl. Acad. Sci. USA 102 (2005) 3930-3935
20. Freytag S.O., Khil M., Stricker H., Peabody J., Menon M., DePeralta-Venturina M., Nafziger D., Pegg J., Paielli D., Brown S., Barton K., Lu M., Aguilar-Cordova E., and Kim J.H. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62 (2002) 4968-4976
21. Freytag S.O., Stricker H., Pegg J., Paielli D., Pradhan D.G., Peabody J., DePeralta-Venturina M., Xia X., Brown S., Lu M., and Kim J.H. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy in combination with conventional dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 63 (2003) 7497-7506
22. Freytag S., Movsas B., Aref I., Stricker H., Peabody J., Pegg J., Zhang Y., Barton K.N., Brown S.L., Lu M., Savera A., and Kim J.H. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy in combination with IMRT for the treatment of newly-diagnosed prostate cancer. Mol. Ther. 15 (2007) 1016-1023
23. Belldegrun A., Tso C.L., Zisman A., Naitoh J., Said J., Pantuck A.J., Hinkel A., deKernion J., and Figlin R. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum. Gene Ther. 12 (2001) 883-892
24. Muller W.J., Lee F.S., Dickson C., Peters G., Pattengale P., and Leder P. The int-2 gene product acts as an epithelial growth factor in transgenic mice. EMBO J. 9 (1990) 907-913
25. Oesterling J.E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol. 14 (1991) 907-923
26. Jurincic C.D., Pixberg H.U., Casser A., and Klippel K.-F. Prostate-specific antigen in prostatic carcinoma. Urol. Int. 45 (1990) 153-159
27. Hamdy F.C., Lawry J., Anderson J.B., Parsons M.A., Rees R.C., and Williams J.L. Circulating prostate specific antigen-positive cells correlate with metastatic prostate cancer. Br. J. Urol. 69 (1992) 392-396
28. Pang S., Taneja S., Dardashti K., Cohan P., Kaboo R., Sokoloff M., Tso C.L., Dekernion J.B., and Belldegrun A.S. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum. Gene Ther. 6 (1995) 1417-1426
29. Gelmann E.P. Molecular biology of the androgen receptor. J. Clin. Oncol. 20 (2002) 3001-3015
30. Matuo Y., Adams P.S., Nishi N., Yasumitsu H., Crabb J.W., Matusik R.J., and McKeehan W.L. The androgen-dependent rat prostate protein, probasin, is a heparin-binding protein that co-purifies with heparin-binding growth factor-1,. In vitro Cell Dev. Biol. 25 (1989) 581-584
31. Dodd J.G., Heppard P.C., and Matusik R.J. Characterization and cloning of highly abundant mRNAs of the rat dorsal prostate. J. Biol. Chem. 258 (1983) 10731-10737
32. Greenberg N.M., Demayo F.J., Sheppard P.C., Barrios R., Lebovitz R., Finegold M., Angelopoulou R., Dodd J.G., Duckworth M.L., and Rosen J.M. The rat probasin gene promoter directed hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol. Endocrinol. 8 (1994) 230-239
33. Greenberg N.M., Demayo F., Finegold M.J., Medina D., Tilley W.D., Aspinall J.O., Cunha G.R., Donjacour A.A., Matusik R.J., and Rosen J.M. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 3439-3443
34. Halter S.A., Dempsey P., Matsui Y., Stokes M.K., Graves-Deal R., Hogan B.L., and Coffey R.J. Distinctive patterns of hyperplasia in MMTV-TGFα transgenic mice: characterization of mammary gland and skin proliferations. Am. J. Pathol. 140 (1992) 1131-1146
35. Matsui Y., Halter S.A., Holt J.T., Hogan B.L., and Coffey R.J. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell 61 (1990) 1147-1155
36. Tutrone R.F., Ball R.A., Ornitz D.M., Leder P., and Richie J.P. Benign prostatic hyperplasia in a transgenic mouse: a new hormonally sensitive investigatory model. J. Urol. 149 (1993) 633-639
37. Steiner M.S., Anthony C.T., Lu Y., and Holt J.T. Antisense c-myc retroviruses vector suppresses established human prostate cancer. Hum. Gene Ther. 9 (1998) 747-755
38. Pierce D.F., Johnson M.D., Matsui Y., Robinson S.D., Gold L.I., Purchio A.F., Daniel C.W., Hogan B.L., and Moses H.L. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGFß1. Genes Dev. 7 (1993) 2308-2317
39. Pierce Jr. P.F., Gorska A.E., Chytil A., Meise K.S., Page D.L., Coffey Jr. R.J., and Moses H.L. Mammary tumor suppression by transforming growth factor ß1 transgene expression. Proc. Natl. Acad. Sci. USA 92 (1995) 4254-4258
40. Steiner M.S., Anthony C., and Paul M. Transforming growth factor ß1 overexpression inhibits seminal vesicle development in transgenic mice. J. Urol. 155 (1996) 350
41. Israeli R.S., Powell C.T., Fair W.R., and Heston W.D. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 53 (1993) 227-230
42. Murtha P., Tindall D.J., and Young C.Y. Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5′ promoter region of the gene. Biochemistry 32 (1993) 6459-6464
43. Young C.Y., Andrews P.E., Montgomery B.T., and Tindall D.J. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 31 (1992) 818-824
44. Charlesworth M.C., Young C.Y., Klee G.G., Saedi M.S., Mikolajczyk S.D., Finlay J.A., and Tindall D.J. Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. Urology 49 (1997) 487-493
45. Saedi M.S., Cass M.M., Goel A.S., Grauer L., Hogen K.L., Okaneya T., Griffin B.Y., Klee G.G., Young C.Y., and Tindall D.J. Overexpression of a human prostate-specific glandular kallikrein, hK2, in E. coli and generation of antibodies. Mol. Cell. Endocrinol. 109 (1995) 237-241
46. Tremblay R.R., Deperthes D., Tetu B., and Dube J.Y. Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors. Am. J. Pathol. 150 (1997) 455-459
47. Parker M.G., White R., Huest H., Needham M., and Tilly R. Prostatic steroid-binding protein. J. Biol. Chem. 258 (1983) 12-15
48. Zhang Y.L., Parker M.G., and Bakker O. Tissue-specific differences in the binding of nuclear proteins to a CCAAT motif in the promoter of the androgen-regulated C3 gene. Mol. Endocrinol. 4 (1990) 1219-1225
49. Tan J.-A., Marschke K.B., Ho K.-C., Perry S.T., Wilson E.M., and French F.S. Response elements of the androgen-regulated C3 gene. J. Biol. Chem. 267 (1992) 4456-4466
50. Maroulakou I.G., Anver M., Garrett L., and Green J.E. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc. Natl. Acad. Sci. USA 91 (1994) 11236-11240
51. McDonnell T.J., Troncoso P., Brisbay S.M., Logothetis C., Chung L.W., Hsieh J.T., Tu S.M., and Campbell M.L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52 (1992) 6940-6944
52. Cross D.S., and Burmester J.K. Functional characterization of the GDEP promoter and three enhancer elements in retinoblastoma and prostate cell lines. Med. Oncol. 25 (2008) 40-49
53. Riegman P.H., Vlietstra R.J., van der Korput J.A., Brinkmann A.O., and Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol. 5 (1991) 1921-1930
54. Pang S., Dannull J., Kaboo R., Xie Y., Tso C.L., Michel K., deKernion J.B., and Belldegrun A.S. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res. 57 (1997) 495-459
55. Dannull J., and Belldegrun A.S. Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen. Br. J. Urol. 79 (1997) 97-103
56. Dannull J., Patel B., Pang S., Kaboo R., and Belldegrun A. Tissue specific expression of a prostate-specific antigen promoter/enhancer in an adenoviral vector used in a human prostate cancer SCID mouse model. J. Urol. 161 (1999) 127
57. Latham J.P., Searle P.F., Mautner V., and James N.D. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. 60 (2000) 334-341
58. Gotoh A., Ko S.C., Shirakawa T., Cheon J., Kao C., Miyamoto T., Gardner T.A., Ho L.J., Cleutjens C.B., Trapman J., Graham F.L., and Chung L.W. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J. Urol. 160 (1998) 220-229
59. Zhang J., Thomas T.Z., Kasper S., and Matusik R.J. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 141 (2000) 4698-4710
60. Ko S.C., Cheon J., Kao C., Gotoh A., Shirakawa T., Sikes R.A., Karsenty G., and Chung L.W.K. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res. 56 (1996) 4614-4619
61. Ou Y., Gardner T.A., Ko S.-C., Zhau H.E., Kao C., and Chung L.W.K. Expression of osteocalcin in canine metastatic prostate cancer: a ideal prostate cancer animal model for osteocalcin promoter-based toxic gene therapy. J. Urol. 161 (1999) 131
62. Gardner T.A., Ko S.C., Kao C., Shirakawa T., Cheon J., Gotoh A., Wu T.T., Sikes R.A., Zhau H.E., Cui Q., Balian G., and Chung L.W.K. Exploiting stromal-epithelial interaction for model development and new strategies of gene therapy for prostate cancer and osteosarcoma metastasis. Gene Ther. Mol. Biol. 2 (1998) 41-58
63. Koeneman K.S., Kao C., Ko S.C., Yang L., Wada Y., Kallmes D.F., Gillenwater J.Y., Zhau H.E., Chung L.W.K., and Gardner T.A. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. World J. Urol. 18 (2000) 102-110
64. Kubo H., Gardner T.A., Wada Y., Koeneman K.S., and Gotoh A. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum. Gene Ther. 14 (2003) 227-241
65. Cairns P., Polascik T.J., Eby Y., Tokino K., Califano J., Merlo A., Mao L., Herath J., Jenkins R., and Westra W. Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nat. Genet. 11 (1995) 210-212
66. Isaacs W.B. Molecular genetics of prostate cancer. Cancer Surv. 25 (1995) 357-379
67. Itoh N., Kakehi Y., Akao T., Kinoshita H., Okada Y., and Yoshida O. Concomitant presence of p16/cyclin-dependent kinase 4 and cyclin D/cyclin-dependent kinase 4 complex in LNCaP prostatic cancer cell line. Jpn. J. Cancer Res. 88 (1997) 229-233
68. Jarrard D.F., Bova G.S., Ewing C.M., Pin S.S., Nguyen S.H., Baylin S.B., Cairns P., Sidransky D., Herman J.G., and Isaacs W.B. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 19 (1997) 90-96
69. Liggett W.H., and Sidransky D. Role of the p16 tumor suppressor gene in cancer. J. Clin. Oncol. 16 (1998) 1197-1206
70. Steiner M.S., Zhang Y., Farooq F., Lerner J., Wang Y., and Lu Y. Adenoviral vector containing wild type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence. Cancer Gene Ther. 7 (2000) 360-372
71. Allay J.A., Steiner M.S., Zhang Y., Reed C.P., Crockroft J., and Lu Y. Adenovirus p16 gene therapy for prostate cancer. World J. Urol. 18 (2000) 111-120
72. Bookstein R., Shew J.Y., Chen P.L., Scully P., and Lee W.H. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247 (1990) 712-715
73. Steiner M.S., Wang Y., Zhang Y., and Lu Y. p16/MTS1/INK4A suppresses prostate cancer by both pRb dependent and independent pathways. Oncogene 19 (2000) 1297-1306
74. Naitoh J., and Bellbegrun A. Gene therapy-the future is here: a guide to the practicing urologist. Urology 51 (1998) 367-380
75. Simons J.W., and Marshall F.F. The future of gene therapy in the treatment of urologic malignancies. Urol. Clin. North Am. 25 (1998) 23-38
76. Navone N.M., Labate M.E., Troncoso P., Pisters L.L., Conti C.J., Eschenbach A.C., and Logothetis C.J. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J. Urol. 161 (1999) 304-308
77. Eastham J.A., Hall S.J., Sehgal I., Wang J., Timme T.L., Yang G., Connell-Crowley L., Elledge S.J., Zhang W.W., and Harper J.W. et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res. 55 (1995) 5151-5155
78. Eastham J.A., Grafton W., Martin C.M., and Williams B.J. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J. Urol. 164 (2000) 814-819
79. Gotoh A., Kao C., Ko S.C., Hamada K., Liu T.J., and Chung L.W. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers. J. Urol. 158 (1997) 636-641
80. Ko S.C., Gotoh A., Thalmann G.N., Zhau H.E., Johnston D.A., Zhang W.W., Kao C., and Chung L.W. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Hum. Gene Ther. 7 (1996) 1683-1691
81. Kleinerman D.I., Zhang W.W., Lin S.H., Nguyen T.V., von Eschenbach A.C., and Hsieh J.T. Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study. Cancer Res. 55 (1995) 2831-2836
82. He D., Mu Z.M., Le X., Hsieh J.T., Pong R.C., Chung L.W., and Chang K.S. Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells. Cancer Res. 57 (1997) 1868-1872
83. Cooke D.B., Quarmby V.E., Mickey D.D., Isaacs J.T., and French F.S. Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostatic adenocarcinoma system. Prostate 13 (1988) 263-272
84. Fleming W.H., Hamel A., MacDonald R., Ramsey E., Pettigrew N.M., Johnson B., Dodd J.G., and Matusik R.J. Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res. 46 (1986) 1535-1538
85. Rijnders A.W.M., Van Der Korput J.A., Van Steenbrugge G.J., Romijn J.C., and Trapman J. Expression of cellular oncogenes in human prostatic carcinoma cell lines. Biochem. Biophys. Res. Commun. 132 (1985) 548-554
86. Elion G.B., Furman P.A., Fyfe J.A., deMiranda P., Beauchamp L., and Schaeffer H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. USA 74 (1977) 5716-5720
87. Field A.K., Davies M.E., DeWitt C., Perry H.C., Liou R., Germershausen J., Karkas J.D., Ashton W.T., Johnston D.B., and Tolman R.L. 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine: a selective inhibitor of herpes group virus replication. Proc. Natl. Acad. Sci. USA 80 (1983) 4139-4143
88. Eastham J.A., Chen S.H., Sehgal J., Yang G., Timme T.L., Hall S.J., Woo S.L., and Thompson T.C. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum. Gene Ther. 7 (1996) 515-523
89. Cheon J., Kim H.K., Moon D.G., Yoon D.K., Cho J.H., and Koh S.K. Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: changes in tumour cell proliferative activity. Br. J. Urol. Int. 85 (2000) 759-766
90. Hall S.J., Sanford M.A., Atkinson G., and Chen S.H. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer. Cancer Res. 58 (1998) 3221-3225
91. Hall S.J., Mutchnik S.E., Yang G., Timme T.L., Nasu Y., Bangma C.H., Woo S.L., Shaker M., and Thompson T.C. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther. 6 (1999) 54-63
92. Hassan W., Sanford M.A., Woo S.L., Chen S.H., and Hall S.J. Prospects for herpes-simplex-virus thymidine-kinase and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer. World J. Urol. 18 (2000) 130-135
93. Martiniello-Wilks R., Garcia-Aragon J., Daja M.M., Russell P., Both G.W., Molloy P.L., Lockett L.J., and Russell P.J. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum. Gene Ther. 9 (1998) 1617-1626
94. Shalev M., Miles B.J., Thompson T.C., Ayala G., Butler E.B., Aguilar-Cordova E., and Kadmon D. Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpes virus thymidine kinase gene. World J. Urol. 18 (2000) 125-129
95. Hall S.J., Mutchnik S.E., Chen S.H., Woo S.L., and Thompson T.C. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int. J. Cancer 70 (1997) 183-187
96. Barba D., Hardin J., Sadelain M., and Gage F.H. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. USA 91 (1994) 4348-4352
97. Gagandeep S., Brew R., Green B., Christmas S.E., Klatzmann D., Poston G.J., and Kinsella A.R. Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect". Cancer Gene Ther. 3 (1996) 83-88
98. Kianmanesh A.R., Perrin H., Panis Y., Fabre M., Nagy H.J., Houssin D., and Klatzmann D. A "distant" bystander effect of suicide gene therapy: regression of nontransduced tumors together with a distant transduced tumor. Hum. Gene Ther. 8 (1997) 1807-1814
99. Vile R.G., Castleden S., Marshall J., Camplejohn R., Upton C., and Chong H. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int. J. Cancer 71 (1997) 267-274
100. Mullen C.A. Cytosine deaminase as a suicide gene in cancer gene therapy. In: Lattime E.C., and Gerson S.L. (Eds). Gene Therapy of Cancer (1999), Academic Press 201-208
101. O'Keefe D.S., Uchida A., Bacich D.J., Watt F.B., Martorana A., Molloy P.L., and Heston W.D. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate 45 (2000) 149-157
102. Blackburn R.V., Galoforo S.S., Corry P.M., and Lee Y.J. Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells. Cancer Res. 58 (1998) 1358-1362
103. Blackburn R.V., Galoforo S.S., Corry P.M., and Lee Y.J. Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity. Int. J. Cancer 82 (1999) 293-297
104. Rodriguez R., Lim H.Y., Bartkowski L.M., and Simons J.W. Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics. Prostate 34 (1998) 259-269
105. Pang S. Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene. Cancer Gene Ther. 7 (2000) 991-996
106. Peng W., Verbitsk A., Bao Y., and Sawicki J. Regulated expression of diphtheria toxin in prostate cancer cells. Mol. Ther. 6 (2002) 537-545
107. Cirielli C., Riccioni T., Yang C., Pili R., Gloe T., Chang J., Inyaku K., Passaniti A., and Capogrossi M.C. Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo. Int. J. Cancer 63 (1995) 673-679
108. Yang C., Cirielli C., Capogrossi M.C., and Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res. 55 (1995) 4210-4213
109. Segawa T., Takebayashi H., Kakehi Y., Yoshida O., Narumiya S., and Kakizuka A. Prostate-specific expanded polyglutamine expression: a novel approach for cancer gene therapy. Cancer Res. 58 (1998) 2282-2287
110. Hedlund T.E., Meech S.J., Srikanth S., Kraft A.S., Miller G.J., Schaack J.B., and Duke R.C. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. Cell Death Differ. 6 (1999) 175-182
111. Hyer M.L., Voelkel-Johnson C., Rubinchik S., Dong J.-Y., and Norris J.S. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. Mol. Ther. 2 (2000) 348-358
112. Marcelli M., Cunningham G.R., Walkup M., He Z., Sturgis L., Kagan C., Mannucci R., Nicoletti I., Teng B., and Denner L. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res. 59 (1999) 382-390
113. Lee S.E., Jin R.J., Lee S.G., Yoon S.J., Park M.S., Heo D.S., and Choi H. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines. Anticancer Res. 20 (2000) 417-422
114. Steiner M.S., Zhang X., Wang Y., and Lu Y. Growth inhibition of prostate cancer by adenovirus expressing a novel tumor suppressor gene pHyde. Cancer Res. 60 (2000) 4419-4425
115. Zhang X., Steiner M.S., Rinaldy A., and Lu Y. Apoptosis induction in prostate cancer cells by a novel gene protein product, pHyde, involves casapase-3. Oncogene 20 (2001) 5982-5990
116. Dorai T., Perlman H., Walsh K., Shabsigh A., Goluboff E.T., Olsson C.A., and Buttyan R. A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells. Int. J. Cancer 82 (1999) 846-852
117. Tolcher A.W. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. Semin. Oncol. 28 suppl (2001) 67-70
118. Moreira J.N., and Santos A. S. Simões. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality. Rev. Recent Clin. Trials 1 (2006) 217-235
119. Blades R.A., Keating P.J., McWilliam L.J., George N.J., and Stern P.L. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 46 (1995) 681-687
120. Sanda M.G., Restifo N.P., Walsh J.C., Kawakami Y., Nelson W.G., Pardoll D.M., and Simons J.W. Molecular characterization of defective antigen processing in human prostate cancer. J. Natl. Cancer Inst. 87 (1995) 280-285
121. Garrido F., and Ruiz-Cabello F. MHC expression on human tumors-its relevance for local tumor growth and metastasis. Semin. Cancer Biol. 2 (1991) 3-10
122. Moody D.B., Robinson J.C., Ewing C.M., Lazenby A.J., and Isaacs W.B. Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo. Prostate 24 (1994) 244-251
123. Kawakita M., Rao G.S., Ritchey J.K., Ornstein D.K., Hudson M.A., Tartaglia J., Paoletti E., Humphrey P.A., Harmon T.J., and Ratliff T.L. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J. Natl. Cancer Inst. 89 (1997) 428-436
124. Schmidt W., Schweighoffer T., Herbst E., Maass G., Berger M., Schilcher F., Schaffner G., and Birnstiel M.L. Cancer vaccines: the interleukin 2 dosage effect. Proc. Natl. Acad. Sci. USA 92 (1995) 4711-4714
125. Vieweg J., Rosenthal F.M., Bannerji R., Heston W.D., Fair W.R., Gansbacher B., and Gilboa E. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res. 54 (1994) 1760-1765
126. Vieweg J., Boczkowski D., Roberson K.M., Edwards D.W., Philip M., Philip R., Rudoll T., Smith C., Robertson C., and Gilboa E. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res. 55 (1995) 2366-2372
127. Sanda M.G., Ayyagari S.R., Jaffee E.M., Epstein J.I., Clift S.L., Cohen L.K., Dranoff G., Pardoll D.M., Mulligan R.C., and Simons J.W. Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol. 151 (1994) 622-628
128. Gansbacher B., Bannerji R., Daniels B., Zier K., Cronin K., and Gilboa E. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 50 (1990) 7820-7825
129. Chen M.E., Lin S.H., Chung L.W., and Sikes R.A. Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. J. Biol. Chem. 273 (1998) 17618-17625
130. Apostolopoulos V., and McKenzie I.F. Cellular mucins: targets for immunotherapy. Crit. Rev. Immunol. 14 (1994) 293-309
131. Carrato C., Balague C., de Bolos C., Gonzalez E., Gambus G., Planas J., Perini J.M., Andreu D., and Real F.X. Differential apomucin expression in normal and neoplastic human gastrointestinal tissues. Gastroenterology 107 (1994) 160-172
132. Gambus G., de Bolos C., Andreu D., Franci C., Egea G., and Real F.X. Detection of the MUC2 apomucin tandem repeat with a mouse monoclonal antibody. Gastroenterology 104 (1993) 93-102
133. Eder J.P., Kantoff P.W., Roper K., Xu G.X., Bubley G.J., Boyden J., Gritz L., Mazzara G., Oh W.K., Arlen P., Tsang K.Y., Panicali D., Schlom J., and Kufe D.W. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 6 (2000) 1632-1638
134. Siemens D.R., Elzey B.D., Lubaroff D.M., Bohlken C., Jensen R.J., Swanson A.K., and Ratliff T.L. Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J. Immunol. 166 (2001) 731-735
135. Sikora K., and Pandha H. Gene therapy for prostate cancer. Br. J. Urol. 79 (1997) 64-68
136. Nasu Y., Bangma C.H., Hull G.W., Lee H.M., Hu J., Wang J., McCurdy M.A., Shimura S., Yang G., Timme T.L., and Thompson T.C. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther. 6 (1999) 338-349
137. Hull G.W., Mccurdy M.A., Nasu Y., Bangma C.H., Yang G., Shimura S., Lee H.M., Wang J., Albani J., Ebara S., Sato T., Timme T.L., and Thompson T.C. Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin. Cancer Res. 6 (2000) 4101-4109
138. Berlyn K.A., Ponniah S., Stass S.A., Malone J.G., Hamlin-Green G., Lim J.K., Cottler-Fox M., Tricot G., Alexander R.B., Mann D.L., and Malone R.W. Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy. J. Biotechnol. 73 (1999) 155-179
139. Nelson W.G., Simons J.W., Mikhak B., Chang J.F., DeMarzo A.M., Carducci M.A., Kim M., Weber C.E., Baccala A.A., Goeman M.A., Clift S.M., Ando D.G., Levitsky H.I., Cohen L.K., Sanda M.G., Mulligan R.C., Partin A.W., Carter H.B., Piantadosi S., and Marshall F.F. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother. Pharmacol. 46 (2000) S67-72
140. Simons J.W., Mikhak B., Chang J.F., DeMarzo A.M., Carducci M.A., Lim M., Weber C.E., Baccala A.A., Goemann M.A., Clift S.M., Ando D.G., Levitsky H.I., Cohen L.K., Sanda M.G., Mulligan R.C., Partin A.W., Carter H.B., Piantadosi S., Marshall F.F., and Nelson W.G. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59 (1999) 5160-5168
141. Simons J.W., Baccala A., and Lim H. Ex vivo and in vivo gene therapy strategies for prostate cancer. In: Lattime E., and Gerson S. (Eds). Emerging Clinical Pharmacology (1999), Academic Press 333-345
142. Trudel S., Trachtenberg J., Toi A., Sweet J., Li Z.H., Jewett M., Tshilias J., Zhuang L.H., Hitt M., Wan Y., Gauldie J., Graham F.L., Dancey J., and Stewart A.K. A phase I trial of adenovector mediated delivery of interleukin-2 (AdIL-2) in high-risk localized prostate cancer. Cancer Gene Ther 10 (2003) 755-763
143. Pantuck A.J., van Ophoven A., Gitlitz B.J., Tso C.L., Acres B., Squiban P., Ross M.E., Belldegrun A.S., and Figlin R.A. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer. J. Immunother. 27 (2004) 240-253
144. Tsai M.J., and Omalley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63 (1994) 451-486
145. Tyagi R.K., Lavrovsky Y., Ahn S.C., Song C.S., Chatterjee B., and Roy A.K. Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol. Endocrinol. 14 (2000) 1162-1174
146. Roche P.J., Hoare S.A., and Parker M.G. A consensus DNA-binding site for the androgen receptor. Mol. Endocrinol. 6 (1992) 2229-2235
147. Cleutjens K.B., van Eekelen C.C., van der Korput H.A., Brinkmann A.O., and Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J. Biol. Chem. 271 (1996) 6379-6388
148. Cleutjens K.B., van der Korput H.A., van Eekelen C.C., van Rooij H.C., Faber P.W., and Trapman J. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol. Endocrinol. 11 (1997) 148-161
149. Shang Y., Myers M., and Brown M. Formation of the androgen receptor transcription complex. Mol. Cell 9 (2002) 601-610
150. Wang Q.B., Carroll J.S., and Brown M. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol. Cell 19 (2005) 631-642
151. Scher H.I., and Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 23 (2005) 8253-8261
152. Harris C., and Hollstein M. Clinical implications of the p53 tumorsuppressor gene. N. Engl. J. Med. 329 (1993) 1318-1326
153. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., and Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51 (1991) 6304-6311
154. Lowe S.W., Ruley H.E., Jacks T., and Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 (1993) 957-967
155. Greenblatt M.S., Bennett W.P., Hollstein M., and Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54 (1994) 4855-4878
156. Lechner M.S., Mack D.H., Finicle A.B., Crook T., Vousden K.H., and Laimins L.A. Human papilloma virus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J. 1 (1992) 3045-3052
157. Gannon J.V., and Lane D.P. p53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature 329 (1987) 456-458
158. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., and McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274 (1996) 373-376
159. Alemany R. Cancer selective adenoviruses. Mol. Aspects Med. 28 (2007) 42-58
160. Khuri F.R., Nemunaitis J., Ganly I., Arseneau J., Tannock I.F., Romel L., Gore M., Ironside J., MacDougall R.H., Heise C., Randlev B., Gillenwater A.M., Bruso P., Kaye S.B., Hong W.K., and Kirn D.H. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6 (2000) 879-885
161. Lamont J.P., Nemunaitis J., Kuhn J.A., Landers S.A., and McCarty T.M. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann. Surg. Oncol. 7 (2000) 588-592
162. Sullivan R., and Graham C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev. 26 (2007) 319-331
163. Chan D.A., and Giaccia A.J. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev. 26 (2007) 333-339
164. Subarsky P., and Hill R.P. The hypoxic tumour microenvironment and metastatic progression. Clin. Exp. Metastasis 20 (2003) 237-250
165. Stackpole C.W., Groszek L., and Kalbag S.S. Benign-tomalignant B16 melanoma progression induced in two stages in vitro by exposure to hypoxia. J. Natl. Cancer Inst. 86 (1994) 361-367
166. Rofstad E.K., and Danielsen T. Hypoxia-induced metastasis of human melanoma cells: involvement of vascular endothelial growth factor-mediated angiogenesis. Br. J. Cancer 80 (1999) 1697-1707
167. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev., Cancer 3 (2003) 721-732
168. M. Hockel, P. Vaupel, Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects, J. Natl. Cancer Inst. 93 (201) 266-276.
169. Lunt S.J., Chaudary N., and Hill R.P. The tumor microenvironment and metastatic disease. Clin. Exp. Metastasis 26 (2009) 19-34
170. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., and Semenza G.L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16 (1996) 4604-4613
171. Michel G., Minet E., Mottet D., Remacle J., and Michiels C. Site-directed mutagenesis studies of the hypoxia-inducible factor-1alpha DNA-binding domain. Biochim. Biophys. Acta 1578 (2002) 73-83
172. Burroughs K.D., Oh J., Barrett J.C., and DiAugustine R.P. Phosphatidylinositol 3-kinase and mek1/2 are necessary for insulin-like growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible factor-1?. Mol. Cancer Res. 1 (2003) 312-322
173. Roth U., Curth K., Unterman T.G., and Kietzmann T. The transcription factors HIF-1 and HNF-4 and the coactivator p300 are involved in insulin-regulated glucokinase gene expression via the phosphatidylinositol 3-kinase/protein kinase B pathway. J. Biol. Chem. 279 (2004) 2623-2631
174. Iliopoulos O., Levy A.P., Jiang C., Kaelin W.G., and Goldberg M.A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 10595-19599
175. Semenza G.L. Hypoxia-inducible factor 1 and cancer pathogenesis. IUBMB Life 60 (2008) 591-597
176. Liao D., Corle C., Seagroves T.N., and Johnson R.S. Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res. 67 (2007) 563-572
177. Hiraga T., Kizaka-Kondoh S., Hirota K., Hiraoka M., and Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res. 67 (2007) 4157-4163
178. Dvorak H.F., Nagy J.A., Feng D., Brown L.F., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237 (1999) 97-132
179. Maynard M.A., and Ohh M. The role of hypoxia-inducible factors in cancer. Cell. Mol. Life Sci. 64 (2007) 2170-2180
180. Yeo E.J., Chun Y.S., Cho Y.S., Kim J., Lee J.C., Kim M.S., and Park J.W. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst. 95 (2003) 516-525
181. Mabjeesh N.J., Escuin D., LaVallee T.M., Pribluda V.S., Swartz G.M., Johnson M.S., Willard M.T., Zhong H., Simons J.W., and Giannakakou P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cells 3 (2003) 363-375
182. Steeg P.S., Hartsough M.T., and Clare S.E. Nm23, breast differentiation, and cancer metastasis. In: Bowcock A.M. (Ed). Breast Cancer (1998), Humana Press, New Jersey 267-283
183. Zhang J., Lu A., Beech D., Jiang B., and Lu Y. Suppression of breast cancer metastasis through the inhibition of VEGF-mediated tumor angiogenesis. Cancer Ther. 5 (2007) 273-286
184. Graham F.L., Smiley J., Russell W.C., and Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36 (1977) 59-72
185. Goldsmith K.T., Curiel D.T., Engler J.A., and Garver Jr. R.I. Trans complementation of an E1a-deleted adenovirus with codelivered E1A sequences to make recombinant adenoviral producer cells. Hum. Gene Ther. 5 (1994) 1341-1348
186. Han J.S., Qian D., Wicha M.S., and Clarke M.F. A method of limited replication for the efficient in vivo delivery of adenovirus to cancer cells. Hum. Gene Ther. 9 (1998) 1209-1216
187. Rodriguez R., Schuur E.R., Lim H.Y., Henderson G.A., Simons J.W., and Henderson D.R. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57 (1997) 2559-2563
188. Yu D.C., Sakamoto G.T., and Henderson D.R. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 59 (1999) 1498-1504
189. Yu D.C., Chen Y., Seng M., Dilley J., and Henderson D.R. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 59 (1999) 4200-4203
190. Su C., Na M., Chen J., Wang X., Liu Y., Wang W., Zhang Q., Li L., Long J., Liu X., Wu M., Fan X., and Qian Q. Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy. Mol. Cancer Res. 6 (2008) 568-575
191. Ahmed A., Thompson J., Emiliusen L., Murphy S., Beauchamp R.D., Suzuki K., Alemany R., Harrington K., and Vile R.G. A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. Nat. Biotechnol. 21 (2003) 771-777
192. Stoff-Khalili M.A., Rivera A.A., Nedeljkovic-Kurepa A., DeBenedetti A., Li X.L., Odaka Y., Podduturi J., Sibley D.A., Siegal G.P., Stoff A., Young S., Zhu Z.B., Curiel D.T., and Mathis J.M. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control. Breast Cancer Res. Treat. 108 (2008) 43-55
193. Nettelbeck D.M. Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer. J. Mol. Med. 86 (2008) 363-377
194. Mineta T., Rabkin S.D., Yazaki T., Hunter W.D., and Martuza R.L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1 (1995) 938-943
195. Yazaki T., Manz H.J., Rabkin S.D., and Martuza R.L. Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 55 (1995) 4752-4756
196. Walker J.R., McGeagh K.G., Sundaresan P., Jorgensen T.J., Rabkin S.D., and Martuza R.L. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum. Gene Ther. 10 (1999) 2237-2243
197. Tai C.K., and Kasahara N. Replication-competent retrovirus vectors for cancer gene therapy. Front. Biosci. 13 (2008) 3083-3095
198. Paielli D.L., Wing M.S., Rogulski K.R., Gilbert J.D., Kolozsvary A., Kim J.H., Hughes J., Schnell M., Thompson T., and Freytag S.O. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. Mol. Ther. 1 (2000) 263-274
199. Freytag S.O., Rogulski K.R., Paielli D.L., Gilbert J.D., and Kim J.H. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9 (1998) 1323-1333
200. Liu Y., Ye T., Sun D., Maynard J., and Deisseroth A. Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma. Hum. Gene Ther. 15 (2004) 637-647
201. Ko D., Hawkins L., and Yu D.C. Development of transcriptionally regulated oncolytic adenoviruses. Oncogene 24 (2005) 7763-7774
202. Sauthoff H., Pipiya T., Heitner S., Chen S., Norman R.G., Rom W.N., and Hay J.G. Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum. Gene Ther. 13 (2002) 1859-1871
203. Sova P., Ren X.W., Ni S., Bernt K.M., Mi J., Kiviat N., and Lieber A. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol. Ther. 9 (2004) 496-509
204. van Beusechem V.W., van den Doel P.B., Grill J., Pinedo H.M., and Gerritsen W.R. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res. 62 (2002) 6165-6171
205. Anello R., Cohen S., Atkinson G., and Hall S.J. Adenovirus mediated cytosine deaminase gene transduction and 5-fluotocytosine therapy sensitizes mouse prostate cancer cells to irradiation. J. Urol. 164 (2000) 2173-2177
206. Atkinson G., and Hall S.J. Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer. Urology 54 (1999) 1098-1104
207. Chung T.D., Mauceri H.J., Hallahan D.E., Yu J.J., Chung S., Grdina W.L., Yajnik S., Kufe D.W., and Weichselbaum R.R. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer. Cancer Gene Ther. 5 (1998) 344-349
208. Gurnani M., Lipari P., Dell J., Shi B., and Nielsen L.L. Adenobirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer. Cancer Chemother. Pharmacol. 44 (1999) 143-151
209. Adams C., Lu Y., Steiner M.S., and Allay J.A. Adenovirus-mediated p16 expression and cisplatin synergize to inhibit human prostate cancer xenograft growth. Mol. Ther. 1 (2000) 163
210. Sandig V., Brand K., Herwig S., Lukas J., Bartek J., and Strauss M. Adenovirally transferred p16INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat. Med. 3 (1997) 313-319
211. Freytag S.O., Stricker H., Movsas B., and Kim J.H. Prostate cancer gene therapy clinical trials. Molec. Ther. 15 (2007) 1042-1052
212. Lee A.K., Levy L.B., Cheung R., and Kuban D. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int. J. Radiat. Oncol. Biol. Phys. 63 (2005) 456-462
213. Valicenti R.K., DeSilvio M., Hanks G.E., Porter A., Brereton H., Rosenthal S.A., Shipley W.U., and Sandler H.M. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer specific survival: an analysis of radiation therapy oncology group protocol 92-02. Int. J. Radiat. Oncol. Biol. Phys. 66 (2006) 1064-1071
214. Small E.J., Carducci M.A., Burke J.M., Rodriguez R., Fong L., van Ummersen L., Yu D.C., Aimi J., Ando D., Working P., Kirn D., and Wilding G. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol. Ther. 14 (2006) 107-117
215. Simons J.W., Mikhak B., Chang J.F., DeMarzo A., Carducci M.A., Lim M., Weber C.E., Baccala A.A., Goemann M.A., Clift S.M., Ando D.G., Levitsky H.I., Cohen L.K., Sanda M.G., Mulligan R.C., Partin A.W., Carter H.B., Piantadosi S., Marshall F.F., and Nelson W.G. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59 (1999) 5160-5168
216. Dranoff G., Jaffee E., Lazenby A., Golumbek P., Levitsky H., Brose K., Jackson V., Hamada H., Pardoll D., and Mulligan R.C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 3539-3543
217. Simons J., Nelson W., Nemuniatis J., Centeno A., Dula E., and Urba W. Phase II trials of a GMCSF gene-transduced prostate cancer cell line vaccine (GVAX) in hormone refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. 22 (2002) 172
218. Small E., Higano C., Smith D., Corman J., Centero A., and Streidle C. A phase 2 study of an allogeneic GM-CSF gene-transduced prostate cancer cell line vaccine in patients with metastatic hormone-refractory prostate cancer (HRPC). J. Clin. Oncol. 22 (2004) 4565
219. Sanda M.G., Ayyagari S.R., Jaffee E.M., Epstein J.I., Clift S.L., Cohen L.K., Dranoff G., Pardoll D.M., Mulligan R.C., and Simons J.W. Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urol. 151 (1994) 622-628
220. Sanda M.G., Smith D.C., Charles L.G., Hwang C., Pienta K.J., Schlom J., Milenic D., Panicali D., and Montie J.E. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53 (1999) 260-266
221. Eder J.P., Kantoff P.W., Roper K., Xu G.X., Bubley G.J., Boyden J., Gritz L., Mazzara G., Oh W.K., Arlen P., Tsang K.Y., Panicali D., Schlom J., and Kufe D.W. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 6 (2000) 1632-1638
222. Gulley J., Chen A.P., Dahut W., Arlen P.M., Bastian A., Steinberg S.M., Tsang K., Panicali D., Poole D., Schlom J., and Michael-Hamilton J. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic, androgen-independent prostate cancer. Prostate 53 (2002) 109-117
223. DiPaola R., Plante M., Kaufman H., Petrylak D., Israeli R., Lattime E., Manson K., and Schuetz T. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J. Transl. Med. 4 (2006) 1-5
224. Demers G.W., Johnson D.E., Tsai V., Wen S.F., Quijano E., Machemer T., Philopena J., Ramachandra M., Howe J.A., Shabram P., Ralston R., and Engler H. Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy. Cancer Res. 63 (2003) 4003-4008
225. Blackwell J.L., Miller C.R., Douglas J.T., Li H., Peters G.E., Carroll W.R., Peters G.E., Strong T.V., and Curiel D.T. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 125 (1999) 856-863
226. Gu D.L., Gonzalez A.M., Printz M.A., Doukas J., Ying W., D'Andrea M., Hoganson D.K., Curiel D.T., Douglas J.T., Sosnowski B.A., Baird A., Aukerman S.L., and Pierce G.F. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res. 59 (1999) 2608-2614
227. Campos S.K., and Barry M.A. Current advances and future challenges in adenoviral vector biology and targeting. Curr Gene Ther. 7 (2007) 189-204
228. Gong M.C., Chang S.S., Watt F., O'Keefe D.S., Bacich D.J., Uchida A., Bander N.H., Reuter V.E., Gaudin P.B., Molloy P.L., Sadelian M., and Heston W.D. Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. Mol. Urol. 4 (2000) 217-222